Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 8 July 2024, 21:10 HKT/SGT
Share:
    

Source: Lexaria Bioscience
Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy
Lexaria currently holding 46 granted patents worldwide

Kelowna, British Columbia, July 8, 2024 - (NewMediaWire) - Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces three new patent awards.

In the European Union, the Company has received a new granted patent in Lexaria’s patent family #6: Transdermal and/or Dermal Delivery of Lipophilic Active Agents. This is the Company’s second granted patent in this patent family with an earlier patent granted in Canada.  This patent will expire in 2039, if not extended and was validated in the following countries:  Austria, Czech Republic, France, UK, Germany, Italy, Poland, Spain, Sweden and Switzerland.

In Canada, Lexaria has received a new granted patent in patent family #18: Compositions and Methods for Enhanced Delivery of Antiviral Agents.  This is the Company’s fourth granted patent in this patent family which was previously granted in the US, Australia, and Japan. This patent will expire in 2041 if not extended.

This patent builds on original research conducted by Lexaria in 2021 wherein the Company evidenced in animal studies that DehydraTECH processing of five different antiviral drugs belonging to three classes of drugs (Protease Inhibitors, Reverse Transcriptase Inhibitors, and Tubulin Polymerization and Microtubule Inhibitor) all were delivered into bloodstream at rates from 42% improvement to 204% improvement, compared to the same drugs not processed with DehydraTECH.

Building on prior patent success in the US related to epilepsy, Lexaria has received its fourth granted US patent in patent family #24, Compositions and Methods for Treating Epilepsy. This patent complements earlier research that discovered DehydraTECH-CBD was capable of mitigating epileptic seizures in rodents, and was also absorbed into the bloodstream more effectively than the commercially available cannabinoid-based anti-seizure medication, Epidiolex®. This patent will expire in 2044 if not extended.

With the issuance of these three new patents, Lexaria’s patent portfolio has now grown to 46 granted patents worldwide. Lexaria’s intellectual property remains a significant component in supporting future business objectives.

About Lexaria Bioscience Corp. & DehydraTECH

DehydraTECH™ is Lexaria’s patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats.  DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 46 patents granted and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company’s ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements.  As such, you should not place undue reliance on these forward-looking statements.  Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company’s ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA).  Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202




Topic: Press release summary
Source: Lexaria Bioscience

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Lexaria Bioscience
May 8, 2024 21:10 HKT/SGT
Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study
May 6, 2024 21:05 HKT/SGT
Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs
Apr 16, 2024 21:10 HKT/SGT
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study
Apr 2, 2024 21:00 HKT/SGT
Lexaria Awarded New Patents
Mar 14, 2024 21:10 HKT/SGT
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
Mar 7, 2024 22:05 HKT/SGT
Lexaria Awards Contract For Next GLP-1 Human Pilot Study
Mar 5, 2024 19:05 HKT/SGT
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
Mar 4, 2024 22:15 HKT/SGT
7% Weight Loss in Animals Supports Lexaria's Next 8-week Animal Study
Mar 1, 2024 21:20 HKT/SGT
Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial
Feb 17, 2024 08:00 HKT/SGT
Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: